Clinical Trials: An Overview of Rescue Clinical Trials

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Since 2010, the greatest annual number of rescue clinical trials occurred in 2018, with 7,657 clinical trials. Phase II outnumbered all other phases, making up to more than 40% of trials; all others were below 20%. Non-industry sponsors had the largest share of rescue clinical trials with over 60%. Single-country trials greatly outnumber multinational trials at more than 75%. North America leads single-country trials, followed by Asia-Pacific, Europe, the Middle East and Africa, and South and Central America. Europe has the most multinational clinical trials, followed by North America, Asia-Pacific, the Middle East & Africa, and South & Central America.

Oncology and indications under its umbrella such as blood cancer, gastrointestinal tract cancer, and lung cancer were the top therapy area and indications tested in rescue clinical trials. Oncology also had the highest percentage of rescue clinical trials to overall trials since 2010. Pembrolizumab was the top drug tested in rescue clinical trials, with the most in ongoing trials. Novartis and National Cancer Institute US are found to be the top sponsors for rescue clinical trials by delayed start date, while GlaxoSmithKline and University of Texas MD Anderson Cancer Center are the top sponsors for rescue clinical trials by delayed end date.

What are the market dynamics of the global rescue clinical trials sector?

When looking at these trials by status, most trials are completed, with over 60% increase from completed for rescue clinical trials by delayed estimated start date. It is expected that there would be little to no planned clinical trials since they have not yet started, and therefore could not have delayed their end dates. Phase II greatly outnumbered all other phases for rescue clinical trials by the delayed estimated end date, making up to more than 40%. Phase I, Phase III, and Phase IV followed up with more than 15%. These are also very similar to those with delayed estimated start dates.

Rescue clinical trials by delayed start date have increased over time since 2010, with the biggest increase seen between 2015 and 2016. Trials with delayed end date increased steadily until plateauing in 2015, and then slowly declined with 2021 having the fewest trials. This may be due to many of the original set end dates not passing and being changed to a new date. The top industry sponsor during this time was GlaxoSmithKline while University of Texas MD Anderson Cancer Center was the top non-industry sponsor.

What are the top regions and countries in the global rescue clinical trials sector?

Like rescue clinical trials by estimated delayed start date, North America has the most overall single-country rescue clinical trial by the delayed estimated end date, with 16,825 trials. This region has the most in all phases, with over 8,000 in Phase II. Europe, Asia-Pacific, Middle East & Africa, and South and Central America follow. Europe has the most multinational clinical trials. North America, the region that has the most single country trials, has the second most multinational trials, followed by Asia-Pacific, the Middle East & Africa, and South and Central America.

When looking at phases, Europe has the most Phase II, Phase III, and Phase IV trials while North America has the most in Phase I. Region statistics for rescue clinical trials by delayed estimated end date are very similar to those with delayed estimated start date, showing no major advantages and/or disadvantages based on location.

Single-country rescue clinical trials by delayed estimated start date, by regionsSingle-country rescue clinical trials by delayed estimated start date, by regions

For more regional insights, download a free report sample

Which are the key companies in the global rescue clinical trials sector?

The top industry sponsor for rescue clinical trials by delayed estimated start date was Novartis with 345 trials. Other major sponsors include GlaxoSmithKline, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Pfizer, AstraZeneca, Eli Lilly, Merck, and Boehringer Ingelheim International.

Global rescue clinical trials sector, by key companies

Global rescue clinical trials sector, by key companies

To know more about key companies, download a free report sample

Market report scope

Key therapy area Oncology, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, Respiratory, Musculoskeletal Disorder, Cardiovascular, and Metabolic Disorders
Key companies Novartis, GlaxoSmithKline, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Pfizer, AstraZeneca, Eli Lilly, Merck, and Boehringer Ingelheim International.

Scope

The clinical trials data used for these analyses were extracted from Global Data’s Clinical Trials Database. The data included clinical trials since 2010, which were captured in the database as of October 28, 2021. The trials were analysed and segmented by all rescue clinical trials, trials with delayed estimated start date, and trials with delayed estimated end date. Further analysis was conducted based on phase, status, multinational vs. single country, sponsor type, top industry and non-industry sponsors, trials utilizing CROs, virtual components, therapy area, and drugs. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Reasons to Buy

  • Understand the rescue trials landscape.
  • The trends of rescue clinical trials with delayed estimated start date.
  • The trends of rescue clinical trials with delayed estimated end date.

Table of Contents

Table of Contents

Executive Summary

Introduction

Rescue Clinical Trials

Rescue Clinical Trials: Delayed Estimated Start Date

Rescue Clinical Trials: Delayed Estimated End Date

Key Findings

Appendix

Figures

List of Figures

Figure 1: Number of Rescue Clinical Trials, by Year

Figure 2: Number of Rescue Clinical Trials, by Single-Country vs. Multinational

Figure 3: Top Reasons for Terminated Trials, by Phase

Figures 4 & 5: Completion Rate of Rescue Clinical Trials, by Use of Virtual Trial Components & CRO

Figure 6: Percent of Rescue Clinical Trials to Overall Clinical Trials Since 2010

Figure 7: Top Drugs Used in Rescue Clinical Trials, by Status

Figure 8: Number of Rescue Clinical Trials by Delayed Estimated Start Date, by Year

Figures 9 & 10: Number of Rescue Clinical Trials by Delayed Estimated Start Date, by Phase & Status

Figure 11: Number of Single-Country Rescue Clinical Trials by Delayed Estimated Start Date, by Region and Phase

Figure 12: Number of Multinational Rescue Clinical Trials by Delayed Estimated Start Date, by Region and Phase

Figure 13: Number of Rescue Clinical Trials by Delayed Estimated Start Date, by Sponsor Type

Figure 14: Top Industry Sponsors for Rescue Clinical Trials by Delayed Estimated Start Date, by Status

Figure 15: Top Non-Industry Sponsors for Rescue Clinical Trials by Delayed Estimated Start Date, by Status

Figure 16: Percent of Rescue Clinical Trials by Delayed Estimated Start Date, by Utilization of CRO & Status

Figure 17: Number of Clinical Trials by Delayed Estimated Start Date, by CRO & Status

Figure 18: Number of Rescue Clinical Trials by Delayed Estimated End Date, by Year

Figures 19 & 20: Number of Rescue Clinical Trials by Delayed Estimated End Date, by Phase & Status

Figure 21: Number of Single-Country Rescue Clinical Trials by Delayed Estimated End Date, by Phase

Figure 22: Number of Multinational Country Rescue Clinical Trials by Delayed Estimated End Date, by Phase

Figure 23: Number of Rescue Clinical Trials by Delayed Estimated End Date, by Sponsor Type

Figure 24: Top Industry Sponsors for Rescue Clinical Trials by Delayed Estimated End Date, by Status

Figure 25: Top Non-Industry Sponsors for Rescue Clinical Trials by Estimated Delayed End Date, by Status

Figure 26: Percent of Rescue Clinical Trials by Estimated Delayed End Date, by Utilization of CRO & Status

Figure 27: Number of Clinical Trials by Delayed Estimated End Date, by CRO & Status

Frequently asked questions

Clinical Trials: An Overview of Rescue Clinical Trials thematic reports
Currency USD
$695

Can be used by individual purchaser only

$2,085

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Clinical Trials: An Overview of Rescue Clinical Trials was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Clinical Trials: An Overview of Rescue Clinical Trials in real time.

  • Access a live Clinical Trials: An Overview of Rescue Clinical Trials dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.